Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | NAAA | Q02083 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PPID | Q08752 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22851911 | 0.98 | NPC1 (0.70) | NPC1TDP1NAAAPOLBPPID | |
| SCHEMBL4398017 | 0.95 | NPC1 (0.65) | NPC1TDP1NAAAPOLBPPID | |
| SCHEMBL6966882 | 0.89 | NPC1 (0.57) | NPC1TDP1NAAAPPID | |
| SCHEMBL9556740 | 0.84 | NPC1 (0.51) | NPC1TDP1NAAAPOLBTSHR | |
| SCHEMBL3141502 | 0.84 | FKBP1A (0.52) | NPC1TDP1NAAAPOLBTSHR | |
| SCHEMBL8391980 | 0.84 | FKBP1A (0.72) | NPC1TDP1NAAAALDH1A1TSHR | |
| SCHEMBL8701414 | 0.83 | NPC1 (0.68) | NPC1TDP1NAAAPOLBALDH1A1 | |
| SCHEMBL13900106 | 0.83 | NPC1 (0.68) | NPC1TDP1NAAAPOLBALDH1A1 | |
| SCHEMBL17087869 | 0.83 | NPC1 (0.96) | NPC1TDP1NAAAPOLBTSHR | |
| SCHEMBL6285963 | 0.83 | NPC1 (0.96) | NPC1TDP1NAAAPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144464-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2019-05-16 | — | — | US | disclosed |
| US-10221190-B2 | Biguanide compounds and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144464-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | GCKR, GCG, SLC5A2 | NPC1 1960/4885TDP1 3647/4885NAAA 3980/4885 |
| US-20150126518-A1 | BIGUANIDE COMPOUNDS AND USE THEREOF | GCKR, GCG, SLC5A2 | NPC1 1960/4885TDP1 3647/4885NAAA 3980/4885 |
| US-10221190-B2 | Biguanide compounds and use thereof | GCKR, GCG, SLC5A2 | NPC1 1960/4885TDP1 3647/4885NAAA 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.